On the recordMay 25, 2016
When we are getting to the left of Europe on some of these issues, we are probably out of the mainstream when it comes to this country.
Source
congress.govEditor's note · Context
Thune comments on the U.S. stance on biotech labeling compared to Europe.
Share
More from John Thune
Jun 18, 2026
I don’t think there ought to be any financial incentives or any financial relief given to Iran absent their commitment to end their nuclear program.
Jun 25, 2026
I look forward to getting this bill through Congress in short order, sending it to the president's desk and delivering another major win for the American people.
Jul 21, 2026
She obviously carries on Lindsey's legacy. But I think she's a very accomplished person in her own right.
Jul 17, 2026
Again, the question is $60 billion worth the risk of putting something like that on the floor, and all the other harm that could potentially come from that.
Other voices in this conversation
